We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RYAM:NYSERayonier Advanced Materials Inc. Analysis

Data as of 2026-07-06 - not real-time

$7.06

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Rayonier Advanced Materials is navigating a pivotal strategic review after the abrupt resignation of its CEO, with Morgan Stanley engaged to explore sale alternatives. The stock is trading below its short‑term moving averages and the RSI is in oversold territory, suggesting potential near‑term upside, while the MACD remains bearish, indicating lingering momentum weakness. Volume has been increasing, reflecting heightened trader interest amid the strategic uncertainty. The company’s fundamentals are strained: margins are negative, free cash flow is negative, and leverage is high, yet valuation multiples such as forward P/E and price‑to‑sales are markedly low, positioning the equity as potentially undervalued. Market sentiment is extremely bullish as reflected by the Fear & Greed index, but the high beta and 48% 30‑day volatility amplify risk.
If a sale or strategic partnership materializes, the upside could be significant, but absent such a catalyst the stock faces pressure from weak earnings, heavy debt, and sector cyclicality. Investors should weigh the short‑term price rebound potential against the longer‑term structural challenges.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • oversold technical indicators (RSI, price below SMA)
  • increasing volume indicating market attention
  • potential upside from strategic review news

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • ongoing strategic review with no definitive outcome
  • persistent negative margins and high debt load
  • volatile price action and high beta

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • possible value realization from a sale or strategic partnership
  • low forward valuation multiples relative to peers
  • industry tailwinds for specialty cellulose products

Key Metrics & Analysis

Financial Health

Revenue Growth-9.50%
Profit Margin-32.82%
P/E Ratio6.5
ROE-100.54%
ROA-0.10%
Debt/Equity316.75
P/B Ratio2.1
Op. Cash Flow$16.2M
Free Cash Flow$-42060752

Technical Analysis

TrendNeutral
RSI27.4
Support$6.97
Resistance$9.37
MA 20$8.15
MA 50$8.75
MA 200$8.10
MACDBearish
VolumeIncreasing
Fear & Greed Index93.63

Valuation

Target Price$14.50
Upside/Downside105.38%
GradeUndervalued
TypeBlend

Risk Assessment

Beta2.00
Volatility48.42%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.